emergent biosolutions inc (EBS) Key Developments
Emergent BioSolutions Wins $44 Million CDC Deal
Aug 13 15
Emergent Biosolutions (EBS) announced that the Centers for Disease Control and Prevention (CDC) has exercised options for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. The contract options, valued at $44 million over two years, will require Emergent to collect plasma for future manufacturing in addition to current collection requirements, conduct manufacturing runs, and conduct additional activities in support of maintaining the FDA licensure of VIGIV.
Emergent BioSolutions, Inc. Presents at Three Part Advisors, LLC Midwest IDEAS Investor Conference 2015, Aug-27-2015 01:10 PM
Aug 11 15
Emergent BioSolutions, Inc. Presents at Three Part Advisors, LLC Midwest IDEAS Investor Conference 2015, Aug-27-2015 01:10 PM. Venue: Hard Rock Hotel, 230 N. Michigan Ave., Chicago, IL 60601, United States.
Emergent BioSolutions, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Earnings Guidance for the Fiscal Year 2015; Provides Revenue Guidance for the Third Quarter of 2015
Aug 6 15
Emergent BioSolutions Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $126.112 million against $110.325 million a year ago. Income from operations was $21.452 million against $7.862 million a year ago. Income before provision for income taxes was $19.600 million against $7.494 million a year ago. Net income was $14.100 million against $5.029 million a year ago. Income per diluted share was $0.32 against $0.13 a year ago. Adjusted net income was $17.0 million against $9.4 million a year ago. Adjusted net income per diluted share was $0.36 against $0.25 a year ago. EBITDA was $29.6 million against $17.2 million a year ago. Adjusted EBITDA was $31.0 million against $20.6 million a year ago. Product sales were $82.023 million against $78.269 million a year ago. The increase in revenue is primarily due to an increase in contracts, grants and collaboration revenues related to its various product development initiatives for which the company receives funding from third parties.
For the six months, the company reported total revenues of $189.745 million against $164.209 million a year ago. Income from operations was $6.858 million against $17.596 million a year ago. Loss before benefit from income taxes was $10.188 million against $20.947 million a year ago. Net loss was $7.419 million against $15.207 million a year ago. Loss per diluted share was $0.19 against $0.41 a year ago. Net cash used in operating activities was $63.370 million against $18.426 million a year ago. Purchases of property, plant and equipment was $19.681 million against $9.400 million a year ago. Product sales were $100.3 million, a decrease of 12% as compared to 2014 product sales of $114.036 million. The decrease was primarily attributable to the timing of deliveries of BioThrax to the SNS due to the company's decision to suspend shipments to the CDC in the first quarter of 2015. Adjusted net loss was $1.8 million against $5.4 million a year ago. Adjusted net loss per diluted share was $0.05 against $0.15 a year ago. EBITDA was $9.6 million against LBITDA of $1.0 million a year ago. Adjusted EBITDA was $12.2 million against $6.7 million a year ago.
The company reaffirmed earnings guidance for the year 2015. For the year, the company expects total revenues of $510 million -$540 million, including $270 million to $285 million of BioThrax sales, GAAP net income of $50 million -$60 million on a GAAP basis and $60 million to $70 million on an adjusted basis.
For the third quarter of 2015, the company expects total revenues of $140 million to $155 million.
Emergent BioSolutions, Inc. Announces Launch of Ruggedized, Military-Grade Auto-Injector Device, Known as Emergard
Aug 3 15
Emergent BioSolutions Inc. announced that it is launching a ruggedized, military-grade auto-injector device, known as Emergard, which is designed for intramuscular self-injection of antidotes and other emergency response medical treatments that can address exposure to certain chemical agents and other similar emerging threats. Emergard is not approved by the U.S. Food and Drug Administration (FDA) and is not currently marketed in the U.S., although the company intends to pursue FDA approval of the device. The company has received preliminary interest for Emergard from countries outside the U.S. and anticipates making its first deliveries in limited quantities in the fourth quarter of 2015. Emergent acquired rights to the device, formerly known as PC-2M, through an exclusive worldwide license agreement with Pharma Consult Ges.m.b.H of Austria, which has been selling the auto-injector in limited quantities to select allied nations. The company has also executed a global manufacturing and supply agreement for Emergard with Nemera Development S.A. Emergent plans to supply cGMP-compliant product through current global sales channels for its other biodefense products. Emergard is designed to be transported, stored, and operated in a military environment and to ensure needle penetration and successful injection through chemical protective gear.
Emergent BioSolutions, Inc. to Report Q2, 2015 Results on Aug 06, 2015
Jul 23 15
Emergent BioSolutions, Inc. announced that they will report Q2, 2015 results at 8:28 PM, GMT Standard Time on Aug 06, 2015